Product Code: GVR-4-68039-014-2
Pharmaceutical Manufacturing Market Growth & Trends
The global pharmaceutical manufacturing market size is expected to reach USD 929.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 7.63% from 2023 to 2030. The pharmaceutical industry has undergone significant transformations as a result of technological advancements, cost-effective methods, and increased investments. These factors have had a positive impact on the growth of the market. The implementation of robotic technology and Artificial Intelligence (AI) has played a crucial role in reducing manufacturing floor downtime and minimizing product waste. By incorporating these technologies, efficiency, and productivity in pharmaceutical manufacturing processes have been greatly improved.
In addition, traditional open-transfer manufacturing methods have been replaced by the adoption of single-use disposable solutions, leading to streamlined operations and reduced risks of contamination. Moreover, there has been a notable shift toward integrated, smart, and data-rich paperless operations within the industry. This transition has resulted in error-free and precise production processes, ensuring the production of high-quality pharmaceutical products. These ongoing advancements in the market have significantly contributed to the progress of drug manufacturing. The development of personalized medicine has brought about a revolution in the healthcare sector, offering new opportunities to target various health conditions and paving the way for patient-centric models.
Consequently, there has been a shift from large-scale production to smaller batches to cater to the development of complex medicines and personalized treatments tailored to individual patients. This transformative shift has prompted manufacturers to restructure their supply chains in alignment with the patient-centric healthcare system. All such factors propel pharmaceutical manufacturing market growth over the forecast period. Furthermore, leading companies in the pharmaceutical industry have taken strategic initiatives to enhance their market presence and gain a competitive advantage. These key players actively engage in various activities, such as product development, collaboration & partnership models, agreements, business expansion, and merger & acquisition strategies.
These initiatives are also aimed at strengthening their product portfolios and meeting the growing demand for pharmaceutical products. For instance, in April 2022, Ferring Pharmaceuticals inaugurated an integrated manufacturing and research and development (R&D) facility in Hyderabad, India. This facility underscores Ferring's commitment to expanding its operations and capabilities. The R&D division of the facility focuses on areas, such as packaging development, formulation development, and analytical development. Ferring Pharmaceuticals aims to enhance its product offerings and meet the evolving needs of the market by investing in these areas.
Pharmaceutical Manufacturing Market Report Highlights
- In 2022, the conventional drugs (small molecules) segment accounted for the highest revenue share of over 54.9%. This is attributed to the easy availability of small molecules products, with high market penetration
- The outsourcing segment dominated the market in 2022 with a revenue share of over 53%. Several benefits associated with outsourcing operations are expected to drive the segment growth at a lucrative pace over the coming years
- In terms of revenue, the tablets segment dominated the market with a share of over 26.08 % in 2022. This is due to the wide availability of tablet-based products and types, such as film and enteric-coated, effervescent, and orally disintegrating tablets
- The oral segment led the global market with a share of more than 58% in 2022. Oral dosage forms are affordable, easy to manufacture, and patient-friendly
- The prescription medicines segment accounted for the maximum revenue share of 83.76% in 2022 and will expand further at a steady CAGR over the forecast period due to the growing prescription drug expenditures across the globe
- North America dominated the market and accounted for a significant revenue share in 2022 due to a large number of strategic pharma partnerships, especially among the well-established and early-stage companies, in this region
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Molecule Type
- 1.2.2. Drug Development Type
- 1.2.3. Formulation
- 1.2.4. Routes of Administration
- 1.2.5. Therapy Area
- 1.2.6. Prescription
- 1.2.7. Age Group
- 1.2.8. Sales Channel
- 1.3. Regional Scope
- 1.4. Estimates and Forecast Timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased database
- 1.6.2. GVR's internal database
- 1.6.3. Secondary sources
- 1.6.4. Primary research
- 1.6.5. Details of primary research
- 1.7. Information or Data Analysis
- 1.7.1. Data analysis models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1.1. Commodity flow analysis (Model 1)
- 1.9.1.2. Approach 1: Commodity flow approach
- 1.9.1.3. Volume price analysis (Model 2)
- 1.9.1.4. Approach 2: Volume price analysis
- 1.10. List of Secondary Sources
- 1.11. List of Primary Sources
- 1.12. Objectives
- 1.12.1. Objective 1
- 1.12.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Molecule Type outlook
- 2.2.2. Drug Development Type outlook
- 2.2.3. Formulation outlook
- 2.2.4. Route of Administration outlook
- 2.2.5. Therapy Area outlook
- 2.2.6. Prescription outlook
- 2.2.7. Age Group outlook
- 2.2.8. Sales Channel outlook
- 2.2.9. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Pharmaceutical Manufacturing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.1.1. Rise in pharmaceutical R&D spending
- 3.3.1.2. Rise in focus toward healthcare needs in emerging nations
- 3.3.1.3. Technological advancements
- 3.3.1.4. Increase in geriatric population and incidence of chronic disorders
- 3.3.2. Market restraint analysis
- 3.3.2.1. Patent expiration of most profitable drugs
- 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
- 3.4. Pharmaceutical manufacturing Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Pharmaceutical Manufacturing: Molecule Type Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.1.1. Biologics & Biosimilars (Large Molecules)
- 4.1.2. Conventional Drugs (Small Molecules)
- 4.2. Molecule Type Market Share, 2022 & 2030
- 4.3. Segment Dashboard
- 4.4. Global Pharmaceutical Manufacturing Market by Molecule Type Outlook
- 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1. Biologics & Biosimilars (Large Molecules)
- 4.5.1.1. Biologics & Biosimilars (Large Molecules) market estimates and forecast 2018 to 2030 (USD Billion)
- 4.5.1.2. Monoclonal Antibodies
- 4.5.1.2.1. Monoclonal Antibodies market estimates and forecast 2018 to 2030 (USD Billion)
- 4.5.1.3. Vaccines
- 4.5.1.3.1. Vaccines market estimates and forecast 2018 to 2030 (USD Billion)
- 4.5.1.4. Cell & Gene Therapy
- 4.5.1.4.1. Cell & Gene Therapy market estimates and forecast 2018 to 2030 (USD Billion)
- 4.5.1.5. Others
- 4.5.1.5.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
- 4.5.2. Conventional Drugs (Small Molecules)
- 4.5.2.1. Conventional Drugs (Small Molecules) market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 5. Pharmaceutical Manufacturing: Drug Development Type Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.1.1. In-house
- 5.1.2. Outsource
- 5.2. Drug Development Type Market Share, 2022 & 2030
- 5.3. Segment Dashboard
- 5.4. Global Microneedle Drug Delivery Systems Market by Drug Development Type Outlook
- 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030for the following
- 5.5.1. In-house
- 5.5.1.1. In-house market estimates and forecast 2018 to 2030 (USD Billion)
- 5.5.2. Outsource
- 5.5.2.1. Outsource market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 6. Pharmaceutical Manufacturing: Formulation Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.1.1. Tablets
- 6.1.2. Capsules
- 6.1.3. Injectable
- 6.1.4. Sprays
- 6.1.5. Suspensions
- 6.1.6. Powders
- 6.1.7. Others
- 6.2. Formulation Market Share, 2022 & 2030
- 6.3. Segment Dashboard
- 6.4. Global Pharmaceutical Manufacturing Market by Formulation Outlook
- 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1. Tablets
- 6.5.1.1. Tablets market estimates and forecast 2018 to 2030 (USD Billion)
- 6.5.2. Capsules
- 6.5.2.1. Capsules market estimates and forecast 2018 to 2030 (USD Billion)
- 6.5.3. Injectable
- 6.5.3.1. Injectable market estimates and forecast 2018 to 2030 (USD Billion)
- 6.5.4. Sprays
- 6.5.4.1. Sprays market estimates and forecast 2018 to 2030 (USD Billion)
- 6.5.5. Suspensions
- 6.5.5.1. Suspensions market estimates and forecast 2018 to 2030 (USD Billion)
- 6.5.6. Powders
- 6.5.6.1. Powders market estimates and forecast 2018 to 2030 (USD Billion)
- 6.5.7. Others
- 6.5.7.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 7. Pharmaceutical Manufacturing: Route of Administration Estimates & Trend Analysis
- 7.1. Definitions and Scope
- 7.1.1. Oral
- 7.1.2. Topical
- 7.1.3. Parenteral
- 7.1.4. Inhalations
- 7.1.5. Others
- 7.2. Route of Administration Market Share, 2022 & 2030
- 7.3. Segment Dashboard
- 7.4. Global Pharmaceutical Manufacturing Market by Route of Administration Outlook
- 7.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.5.1. Oral
- 7.5.1.1. Oral market estimates and forecast 2018 to 2030 (USD Billion)
- 7.5.2. Topical
- 7.5.2.1. Topical market estimates and forecast 2018 to 2030 (USD Billion)
- 7.5.3. Parenteral
- 7.5.3.1. Parenteral market estimates and forecast 2018 to 2030 (USD Billion)
- 7.5.4. Inhalations
- 7.5.4.1. Inhalations market estimates and forecast 2018 to 2030 (USD Billion)
- 7.5.5. Others
- 7.5.5.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 8. Pharmaceutical Manufacturing: Therapy Area Estimates & Trend Analysis
- 8.1. Definitions and Scope
- 8.1.1. Cardiovascular diseases
- 8.1.2. Pain
- 8.1.3. Diabetes
- 8.1.4. Cancer
- 8.1.5. Respiratory diseases
- 8.1.6. Others
- 8.2. Therapy Area Market Share, 2022 & 2030
- 8.3. Segment Dashboard
- 8.4. Global Pharmaceutical Manufacturing Market by Therapy Area Outlook
- 8.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 8.5.1. Cardiovascular diseases
- 8.5.1.1. Cardiovascular diseases market estimates and forecast 2018 to 2030 (USD Billion)
- 8.5.2. Pain
- 8.5.2.1. Pain market estimates and forecast 2018 to 2030 (USD Billion)
- 8.5.3. Diabetes
- 8.5.3.1. Diabetes market estimates and forecast 2018 to 2030 (USD Billion)
- 8.5.4. Cancer
- 8.5.4.1. Cancer market estimates and forecast 2018 to 2030 (USD Billion)
- 8.5.5. Respiratory diseases
- 8.5.5.1. Respiratory diseases market estimates and forecast 2018 to 2030 (USD Billion)
- 8.5.6. Others
- 8.5.6.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 9. Pharmaceutical Manufacturing: Prescription Estimates & Trend Analysis
- 9.1. Definitions and Scope
- 9.1.1. Prescription Medicines
- 9.1.2. Over-the-counter (OTC) medicines
- 9.2. Prescription Market Share, 2022 & 2030
- 9.3. Segment Dashboard
- 9.4. Global Pharmaceutical Manufacturing Market by Prescription Outlook
- 9.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 9.5.1. Prescription Medicines
- 9.5.1.1. Prescription Medicines market estimates and forecast 2018 to 2030 (USD Billion)
- 9.5.2. Over-the-counter (OTC) medicines
- 9.5.2.1. Over-the-counter (OTC) medicines market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 10. Pharmaceutical Manufacturing: Age Group Estimates & Trend Analysis
- 10.1. Definitions and Scope
- 10.1.1. Children & Adolescents
- 10.1.2. Adults
- 10.1.3. Geriatric
- 10.2. Age Group Market Share, 2022 & 2030
- 10.3. Segment Dashboard
- 10.4. Global Pharmaceutical Manufacturing Market by Age Group Outlook
- 10.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030for the following
- 10.5.1. Children & Adolescents
- 10.5.1.1. Children & Adolescents market estimates and forecast 2018 to 2030 (USD Billion)
- 10.5.2. Adults
- 10.5.2.1. Adults market estimates and forecast 2018 to 2030 (USD Billion)
- 10.5.3. Geriatric
- 10.5.3.1. Geriatric market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 11. Pharmaceutical Manufacturing: Sales Channel Estimates & Trend Analysis
- 11.1. Definitions and Scope
- 11.1.1. Retail
- 11.1.2. Non-retail
- 11.2. Sales Channel Market Share, 2022 & 2030
- 11.3. Segment Dashboard
- 11.4. Global Pharmaceutical Manufacturing Market by Sales Channel Outlook
- 11.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 11.5.1. Retail
- 11.5.1.1. Retail market estimates and forecast 2018 to 2030 (USD Billion)
- 11.5.2. Non-retail
- 11.5.2.1. Non-retail market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 12. Pharmaceutical Manufacturing Market: Regional Estimates & Trend Analysis
- 12.1. Regional market share analysis, 2022 & 2030
- 12.2. Regional Market Dashboard
- 12.3. Global Regional Market Snapshot
- 12.4. Regional Market Share and Leading Players, 2021
- 12.4.1. North America
- 12.4.2. Europe
- 12.4.3. Asia Pacific
- 12.4.4. Latin America
- 12.4.5. Middle East and Africa
- 12.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
- 12.5.1. North America
- 12.5.2. Europe
- 12.5.3. Asia Pacific
- 12.5.4. Latin America
- 12.5.5. Middle East and Africa
- 12.6. Market Size, & Forecasts, Volume and Trend Analysis, 2018 to 2030:
- 12.7. North America
- 12.7.1. SWOT Analysis
- 12.7.2. North America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.7.3. U.S.
- 12.7.3.1. Key Country Dynamics
- 12.7.3.2. Target Disease Prevalence
- 12.7.3.3. Competitive Scenario
- 12.7.3.4. Regulatory Framework
- 12.7.3.5. U.S. Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.7.4. Canada
- 12.7.4.1. Key Country Dynamics
- 12.7.4.2. Target Disease Prevalence
- 12.7.4.3. Competitive Scenario
- 12.7.4.4. Regulatory Framework
- 12.7.4.5. Canada Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8. Europe
- 12.8.1. SWOT Analysis
- 12.8.2. Europe Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.3. UK
- 12.8.3.1. Key Country Dynamics
- 12.8.3.2. Target Disease Prevalence
- 12.8.3.3. Competitive Scenario
- 12.8.3.4. Regulatory Framework
- 12.8.3.5. UK Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.4. Germany
- 12.8.4.1. Key Country Dynamics
- 12.8.4.2. Target Disease Prevalence
- 12.8.4.3. Competitive Scenario
- 12.8.4.4. Regulatory Framework
- 12.8.4.5. Germany Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.5. France
- 12.8.5.1. Key Country Dynamics
- 12.8.5.2. Target Disease Prevalence
- 12.8.5.3. Competitive Scenario
- 12.8.5.4. Regulatory Framework
- 12.8.5.5. France Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.6. Italy
- 12.8.6.1. Key Country Dynamics
- 12.8.6.2. Target Disease Prevalence
- 12.8.6.3. Competitive Scenario
- 12.8.6.4. Regulatory Framework
- 12.8.6.5. Italy Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.7. Spain
- 12.8.7.1. Key Country Dynamics
- 12.8.7.2. Target Disease Prevalence
- 12.8.7.3. Competitive Scenario
- 12.8.7.4. Regulatory Framework
- 12.8.7.5. Spain Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.8. Denmark
- 12.8.8.1. Key Country Dynamics
- 12.8.8.2. Target Disease Prevalence
- 12.8.8.3. Competitive Scenario
- 12.8.8.4. Regulatory Framework
- 12.8.8.5. Denmark Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.9. Sweden
- 12.8.9.1. Key Country Dynamics
- 12.8.9.2. Target Disease Prevalence
- 12.8.9.3. Competitive Scenario
- 12.8.9.4. Regulatory Framework
- 12.8.9.5. Sweden Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.8.10. Norway
- 12.8.10.1. Key Country Dynamics
- 12.8.10.2. Target Disease Prevalence
- 12.8.10.3. Competitive Scenario
- 12.8.10.4. Regulatory Framework
- 12.8.10.5. Norway Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.9. Asia Pacific
- 12.9.1. SWOT Analysis
- 12.9.2. Asia Pacific Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.9.3. China
- 12.9.3.1. Key Country Dynamics
- 12.9.3.2. Target Disease Prevalence
- 12.9.3.3. Competitive Scenario
- 12.9.3.4. Regulatory Framework
- 12.9.3.5. China Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.9.4. Japan
- 12.9.4.1. Key Country Dynamics
- 12.9.4.2. Target Disease Prevalence
- 12.9.4.3. Competitive Scenario
- 12.9.4.4. Regulatory Framework
- 12.9.4.5. Japan Market estimates and forecast, 2018 - 2030 (Volume, Thousand)
- 12.9.5. India
- 12.9.5.1. Key Country Dynamics
- 12.9.5.2. Target Disease Prevalence
- 12.9.5.3. Competitive Scenario
- 12.9.5.4. Regulatory Framework
- 12.9.5.5. India Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.9.6. Australia
- 12.9.6.1. Key Country Dynamics
- 12.9.6.2. Target Disease Prevalence
- 12.9.6.3. Competitive Scenario
- 12.9.6.4. Regulatory Framework
- 12.9.6.5. Australia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.9.7. Thailand
- 12.9.7.1. Key Country Dynamics
- 12.9.7.2. Target Disease Prevalence
- 12.9.7.3. Competitive Scenario
- 12.9.7.4. Regulatory Framework
- 12.9.7.5. Thailand Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.9.8. South Korea
- 12.9.8.1. Key Country Dynamics
- 12.9.8.2. Target Disease Prevalence
- 12.9.8.3. Competitive Scenario
- 12.9.8.4. Regulatory Framework
- 12.9.8.5. South Korea Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.10. Latin America
- 12.10.1. SWOT Analysis
- 12.10.2. Latin America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.10.3. Brazil
- 12.10.3.1. Key Country Dynamics
- 12.10.3.2. Target Disease Prevalence
- 12.10.3.3. Competitive Scenario
- 12.10.3.4. Regulatory Framework
- 12.10.3.5. Brazil Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.10.4. Mexico
- 12.10.4.1. Key Country Dynamics
- 12.10.4.2. Target Disease Prevalence
- 12.10.4.3. Competitive Scenario
- 12.10.4.4. Regulatory Framework
- 12.10.4.5. Mexico Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.10.5. Argentina
- 12.10.5.1. Key Country Dynamics
- 12.10.5.2. Target Disease Prevalence
- 12.10.5.3. Competitive Scenario
- 12.10.5.4. Regulatory Framework
- 12.10.5.5. Argentina Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.11. MEA
- 12.11.1. SWOT Analysis
- 12.11.2. MEA Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.11.3. Saudi Arabia
- 12.11.3.1. Key Country Dynamics
- 12.11.3.2. Target Disease Prevalence
- 12.11.3.3. Competitive Scenario
- 12.11.3.4. Regulatory Framework
- 12.11.3.5. Saudi Arabia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.11.4. South Africa
- 12.11.4.1. Key Country Dynamics
- 12.11.4.2. Target Disease Prevalence
- 12.11.4.3. Competitive Scenario
- 12.11.4.4. Regulatory Framework
- 12.11.4.5. South Africa Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.11.5. UAE
- 12.11.5.1. Key Country Dynamics
- 12.11.5.2. Target Disease Prevalence
- 12.11.5.3. Competitive Scenario
- 12.11.5.4. Regulatory Framework
- 12.11.5.5. UAE Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
- 12.11.6. Kuwait
- 12.11.6.1. Key Country Dynamics
- 12.11.6.2. Target Disease Prevalence
- 12.11.6.3. Competitive Scenario
- 12.11.6.4. Regulatory Framework
- 12.11.6.5. Kuwait Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
Chapter 13. Competitive Landscape
- 13.1. Recent Developments & Impact Analysis, By Key Market Participants
- 13.2. Company/Competition Categorization
- 13.3. Vendor Landscape
- 13.3.1. List of key distributors and channel partners
- 13.3.2. Key customers
- 13.3.3. Key company market share analysis, 2022
- 13.3.4. F. Hoffmann-La Roche Ltd.
- 13.3.4.1. Company overview
- 13.3.4.2. Financial performance
- 13.3.4.3. Product benchmarking
- 13.3.4.4. Strategic initiatives
- 13.3.5. Novartis AG
- 13.3.5.1. Company overview
- 13.3.5.2. Financial performance
- 13.3.5.3. Product benchmarking
- 13.3.5.4. Strategic initiatives
- 13.3.6. GlaxoSmithKline plc
- 13.3.6.1. Company overview
- 13.3.6.2. Financial performance
- 13.3.6.3. Product benchmarking
- 13.3.6.4. Strategic initiatives
- 13.3.7. Pfizer, Inc.
- 13.3.7.1. Company overview
- 13.3.7.2. Financial performance
- 13.3.7.3. Product benchmarking
- 13.3.7.4. Strategic initiatives
- 13.3.8. Merck & Co., Inc.
- 13.3.8.1. Company overview
- 13.3.8.2. Financial performance
- 13.3.8.3. Product benchmarking
- 13.3.8.4. Strategic initiatives
- 13.3.9. AstraZeneca
- 13.3.9.1. Company overview
- 13.3.9.2. Financial performance
- 13.3.9.3. Product benchmarking
- 13.3.9.4. Strategic initiatives
- 13.3.10. Johnson & Johnson Services, Inc.
- 13.3.10.1. Company overview
- 13.3.10.2. Financial performance
- 13.3.10.3. Product benchmarking
- 13.3.10.4. Strategic initiatives
- 13.3.11. Sanofi SA
- 13.3.11.1. Company overview
- 13.3.11.2. Financial performance
- 13.3.11.3. Product benchmarking
- 13.3.11.4. Strategic initiatives
- 13.3.12. Eli Lilly and Company
- 13.3.12.1. Company overview
- 13.3.12.2. Financial performance
- 13.3.12.3. Product benchmarking
- 13.3.12.4. Strategic initiatives
- 13.3.13. AbbVie, Inc.
- 13.3.13.1. Company overview
- 13.3.13.2. Financial performance
- 13.3.13.3. Product benchmarking
- 13.3.13.4. Strategic initiatives
- 13.3.14. Thermo Fisher Scientific, Inc.
- 13.3.14.1. Company overview
- 13.3.14.2. Financial performance
- 13.3.14.3. Product benchmarking
- 13.3.14.4. Strategic initiatives
- 13.3.15. Wuxi Apptec
- 13.3.15.1. Company overview
- 13.3.15.2. Financial performance
- 13.3.15.3. Product benchmarking
- 13.3.15.4. Strategic initiatives
- 13.3.16. Samsung Biologics
- 13.3.16.1. Company overview
- 13.3.16.2. Financial performance
- 13.3.16.3. Product benchmarking
- 13.3.16.4. Strategic initiatives
- 13.3.17. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- 13.3.17.1. Company overview
- 13.3.17.2. Financial performance
- 13.3.17.3. Product benchmarking
- 13.3.17.4. Strategic initiatives
- 13.3.18. Lonza
- 13.3.18.1. Company overview
- 13.3.18.2. Financial performance
- 13.3.18.3. Product benchmarking
- 13.3.18.4. Strategic initiatives
- 13.3.19. Catalent Pharma Solutions
- 13.3.19.1. Company overview
- 13.3.19.2. Financial performance
- 13.3.19.3. Product benchmarking
- 13.3.19.4. Strategic initiatives
- 13.3.20. Jubilant Pharmova Limited
- 13.3.20.1. Company overview
- 13.3.20.2. Financial performance
- 13.3.20.3. Product benchmarking
- 13.3.20.4. Strategic initiatives